Depression is a mental condition characterized by a continuous sense of sadness as well as a loss of interest. It affects how patients feel, think, and behave and can lead to a variety of mental and physical difficulties. It is also known as major depressive disorder or clinical depression. Patients may find it difficult to carry out day-to-day tasks. Depression is a widespread and significant medical condition that has a detrimental impact on how people feel, think, and act. Patients with depression experience melancholy and/or a loss of interest in activities they once enjoyed. It can cause a wide range of emotional and physical issues. Antidepressants, which are pharmaceuticals that can help relieve depression symptoms, are one type of drug that can be used to treat depression. Antidepressants, which are pharmaceuticals that can help reduce symptoms of depression, social anxiety disorder, anxiety disorders, and seasonal affective disorder, are among the treatments available for treating depression. Atypical antipsychotics, also known as second generation antipsychotics and serotonin–dopamine antagonists, are a class of antipsychotic medicines that were developed to treat psychiatric disorders.
Global treatment resistant depression market is estimated to be valued at US$ 1,180.0 Mn in 2022 and is expected to exhibit a CAGR of 3.4% over the forecast period (2022-2030).
Figure 1: Global Treatment Resistant Depression Market Share (%) Analysis, By Drug Type, 2022
Key players in market are involved in gaining approvals for their novel treatment resistant depression drugs and launching them in market. Such approval and launch of novel drugs indicated for treatment resistant depression is expected to drive market growth over the forecast period.
Key players in market are involved in gaining approvals for their novel treatment resistant depression drugs and launching them in market. Such approval and launch of novel drugs indicated for treatment resistant depression is expected to drive market growth over the forecast period. For instance, In January 2022, Denovo Biopharma LLC, is a clinical-stage biopharmaceutical company focused on the development of biomarker-driven precision medicines, has announced that the U.S. Food and Drug Administration (FDA) authorized the company's investigational new drug (IND) application of DB104 (liafensine) for treatment-resistant depression (TRD) to proceed, which enables Denovo to start a global Phase 2b clinical trial to assess the safety and efficacy of liafensine in patients with TRD
Increasing prevalence of depression is expected to drive growth of the global treatment resistant depression market over the forecast period.
Increasing prevalence of depression is expected to drive growth of the global treatment resistant depression market over the forecast period. For instance, according to data published by National Institute of Mental Health in January 2022, an estimated 21.0 million adults in the U.S. had at least one major depressive episode in 2020. This number represented 8.4% of all the U.S. adults in 2020.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2021 | Market Size in 2022: | US$ 1,180.0 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
| Forecast Period 2022 to 2030 CAGR: | 3.4% | 2030 Value Projection: | US$ 1,545.6 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
AbbVie Inc., Lupin, Eli Lilly and Company, GlaxoSmithKline Plc., Pfizer Inc., Bausch Health Companies Inc., Sanofi, Mallinckrodt, Johnson & Johnson, Merck & Co., Inc., Viatris Inc., Otsuka Holdings Co., Ltd., H. Lundbeck A/S, AstraZeneca, and Aurobindo Pharma Ltd. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Global Treatment Resistant Depression Market- Impact of the Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic has hampered and disrupted the overall healthcare facilities all over the globe. For instance, according to a review article published by the European Pharmaceutical Review journal in November 2020, COVID-19 pandemic has caused major challenges with respect to drug shortages and increased manufacturing costs across the globe. Moreover, the same source stated that COVID-19 pandemic has also led to problems such as stockpiling drugs, transportation delay, and others. Some measures that can be taken to ease the supply of pharmaceuticals during the pandemic include next generation technologies such as digital network platforms designed to work across multiple pharmaceutical enterprises and ensure the timely delivery of drugs to patients across the globe.
Global Treatment Resistant Depression Market– Restraints
High cost of drugs used as treatment resistant depression medication is expected to restraint market growth over the forecast period. For instance, in March 2019, Johnson & Johnson announced that its nasal spray depression treatment, called Spravato, and global price will be at US$ 590 for a 56 mg dose and US$ 885 for 84 mg.
Adverse drug reactions associated with treatment resistant depression medication is expected to restraint market growth over the forecast period. The most commonly observed adverse reactions in patients treated with SPRAVATO plus oral antidepressant (AD) were dissociation, dizziness, nausea, sedation, vertigo, hypoesthesia, anxiety, lethargy, blood pressure increase, vomiting, intoxication, and others.
Global Treatment Resistant Depression Market– Regional Analysis
On the basis of region, the global treatment resistant depression market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Among regions, North America market is expected to witness significant growth, owing to key companies in market focusing on adopting inorganic strategies such as partnerships to research on treatment-resistant depression and its treatment. For instance, in March 2021, Novamind, a mental health company, announced that its wholly-owned subsidiary, Cedar Clinical Research, had been selected as a key research site for a clinical trial focused on treatment-resistant depression by Merck & Co. The phase II study would assess the efficacy and safety of a new Merck drug, MK-1942 for treatment-resistant depression (TRD).
Figure 2: Global Treatment Resistant Depression Market Value (US$ Mn), by Region, 2022
Global Treatment Resistant Depression Market– Competitive Landscape
Major players operating in the global treatment resistant depression market include AbbVie Inc., Lupin, Eli Lilly and Company, GlaxoSmithKline Plc., Pfizer Inc., Bausch Health Companies Inc., Sanofi, Mallinckrodt, Johnson & Johnson, Merck & Co., Inc., Viatris Inc., Otsuka Holdings Co., Ltd., H. Lundbeck A/S, AstraZeneca, and Aurobindo Pharma Ltd.
Depression is a mood disorder that causes a persistent feeling of sadness and a loss of interest. Also called major depressive disorder or clinical depression, it affects how patients feel, think, and behave and can lead to a variety of emotional and physical problems. Patients may have trouble doing normal day-to-day activities. Depression (major depressive disorder) is a common and serious medical illness that negatively affects how patients feel, the way they think, and how they act. Depression causes feelings of sadness and/or a loss of interest in activities patients once enjoyed. It can lead to a variety of emotional and physical problems. There are various drugs available for treatment of depression, such as antidepressants, which are medications that can help relieve symptoms of depression, social anxiety disorder, anxiety disorders, and seasonal affective disorder. The atypical agents, also known as second generation antipsychotics and serotonin–dopamine antagonists, are a group of antipsychotic drugs largely introduced to be used to treat psychiatric conditions.
Market Dynamics
Increasing inorganic activities such as fund raise by organizations in order to expand their presence in the global treatment resistant depression market is expected to drive the market growth over forecast period. For instance, in February 2022, Minded, the specialist in prescribing mental health medication online, announced US$ 25 million in seed funding. Investors included Streamlined Ventures, Link Ventures, The Tiger Fund, Unicorn Ventures, Trousdale Ventures, Gaingels, SALT Fund, TheFund, and the founders of Care.com, Bolt, Gravity Blanket, RXBAR, and Gilt.com, along with venture debt from Western Technology Investment (WTI).
Increasing development of novel therapeutics for the treatment of resistant depression by market players to launch their novel products is expected to drive market growth over forecast period. For instance, in September 2021, XWPharma Ltd., a biopharmaceutical company, announced dosing of subjects in its first-in-human study evaluating XW10508, the company’s novel, patented, glutamatergic NMDA antagonist and AMPA activator in development as an oral, once-daily therapy for the treatment of treatment-resistant depression and chronic pain.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients